Sartorius acquires majority stake in CellGenix

Portfolio expanded by cell culture components, such as growth factors, cytokines, and media

05-Jul-2021 - Germany

The life science group Sartorius, through its subgroup Sartorius Stedim Biotech, has acquired a majority stake in the reagent manufacturer CellGenix GmbH. The company based in Freiburg, Germany, and with a sales subsidiary near the biotechnology hub in Boston, Massachusetts USA, produces and markets cell culture components, such as growth factors, cytokines and media in GMP quality for manufacturing cell and gene therapy products.

Sartorius AG

Sartorius has initially acquired 51 percent of this company, which has been privately owned until now, for around 100 million euros in cash. At the beginning of 2023 and 2026, Sartorius plans to acquire the remaining shares of CellGenix. Founded in 1994 at the University Medical Center of Freiburg, CellGenix currently employs some 70 people and generated sales of more than 20 million euros in 2020, achieving a very significant double-digit EBITDA margin.

“CellGenix has an excellent reputation on the market and brings in high technological expertise and considerable regulatory experience in one of the fastest-growing fields of the biopharma sector. Together, we will support our customers even better in fast-tracking their drug candidates efficiently through the various steps in the development of medicines so that innovative therapies can reach patients faster,” said René Fáber, member of the Executive Board for the Bioprocess Solutions Division of Sartorius.

“For us, Sartorius is an ideal partner with a highly complementary product portfolio that will accelerate our development with its global sales team, enabling us to usher in our next phase of growth,” added Felicia Rosenthal, CEO and co-founder of CellGenix.

Sartorius plans to expand the Freiburg site substantially and to establish it as a center of excellence within the group in the areas of development and manufacture of quality critical raw materials for the cell and gene therapy market.

Other news from the department business & finance

These products might interest you

Micro-Dx™ CE IVD

Micro-Dx™ CE IVD by Molzym

Fully automated from sample to PCR analysis

Rapid identification of bacteria and fungi without time-consuming cultivation

DNA extraction kits
DNA-free Taq Polymerases and Mastermixes

DNA-free Taq Polymerases and Mastermixes by Molzym

DNA-free reagents for unrivalled sensitivity in molecular biology

Purity that makes the difference

PCR accessories
Greener Alternative Products

Greener Alternative Products by Merck Life Science

Sustainable laboratory products for environmentally conscious research

Over 2,500 ecological alternatives to reduce your laboratory footprint

consumables
CellGenix® Growth Factors and Cytokines

CellGenix® Growth Factors and Cytokines by Sartorius

Recombinant growth factors without animal products

Optimised cell culture for T cells and MSCs in gene therapy

reagents
Recombumin® Elite

Recombumin® Elite by Sartorius

ICHQ7 cGMP-compliant albumin for biotechnological applications

Increase consistency and safety for gene therapies and vaccines

reagents
DNA/RNA Shield™ SafeCollect Collection Kits

DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research

Sample collection devices for simple & safe at-home testing

Best user experience for secure self-collection

kits
Loading...

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.

View topic world
Topic world Gene therapy

Topic world Gene therapy

Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.

Topic world Cell culture technology

Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.

3 whitepaper
View topic world
Topic world Cell culture technology

Topic world Cell culture technology

Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.

3 whitepaper